Key result
Lipid emulsion infusion is a promising treatment for racemic bupivacaine-induced cardiac asystole, but evidence does not support its use as a panacea for all local anesthetic toxicity.
Why the study?
Does lipid emulsion infusion reverse cardiac asystole in patients with racemic bupivacaine-induced cardiotoxicity?
Population
Patients experiencing racemic bupivacaine-induced cardiac asystole
Design
Editorial
Authors
Loading...
While lipid emulsion is a promising antidote for bupivacaine-induced asystole, the author emphasizes that preventing toxicity by using safer local anesthetics should be the primary strategy.
Does lipid emulsion infusion reverse cardiac asystole in patients with racemic bupivacaine-induced cardiotoxicity?
While lipid emulsion is a promising antidote for bupivacaine-induced asystole, the author emphasizes that preventing toxicity by using safer local anesthetics should be the primary strategy.
Rudolph H. de Jong (2007) conducted a letter in Racemic bupivacaine-induced cardiotoxicity. Lipid emulsion infusion vs. Conventional advanced cardiac life support was evaluated. Lipid emulsion infusion is a promising treatment for racemic bupivacaine-induced cardiac asystole, but evidence does not support its use as a panacea for all local anesthetic toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: